Comparing the current results to its competitors, Organon And Co reported Revenue decrease in the 2 quarter 2026 year on year by -2.26 %, despite the revenue increase by the most of its competitors of 5.18 %, recorded in the same quarter.
Organon and Co Net Income in the 2 quarter 2026 fell year on year by -25.52%, while most of its competitors have experienced a contraction in net income by -69.57 %.
Organon And Co 's Comment on Competition and Industry Peers
The company operates in competitive pharmaceutical markets, facing competition from global research-based pharmaceutical firms, smaller specialized research companies, and generic drug manufacturers. Its operations may be impacted by generic and biosimilar competition as products mature, technological advancements by competitors, industry consolidation, patents held by competitors, competitive combination products, new competitor products, generic availability of competitors' branded products, and new clinical trial or post-marketing surveillance data. Patent rights are frequently challenged by competitors, with uncertain outcomes that could prevent product commercialization, reduce sales, or lead to royalty payments or impairment charges.
July 10, 2025
Organon and Co., a notable player in the biopharmaceutical sector, is currently facing significant legal challenges as a class action lawsuit has been filed against the company. This litigation, spearheaded by prominent law firms Pomerantz LLP and Levi and Korsinsky LLP, seeks to address alleged investment losses experienced by shareholders. As the company finds itself in the legal crosshairs, it raises important questions about investor trust, market stability, and the potential consequences for the biopharmaceutical giant. Key Facts1. Class Action Lawsuit Filed : Pomerantz LLP and Levi and Korsinsky LLP have initiated a class action lawsuit against Organon and Co. targeting investors who have reportedly ...
June 12, 2025
Organon Shareholder Alert: Investors Urged to Act Amid Class Action Lawsuit Due to Underperformance In a noteworthy development for shareholders of Organon and Co. (NYSE: OGN), ClaimsFiler has issued a reminder to investors who have suffered losses exceeding $100,000 to file lead plaintiff applications in an ongoing class action lawsuit. The deadline for this filing is set for July 22, 2025, and pertains to those who acquired the company’s securities between October 31, 2024, and April 30, 2025. This legal action is currently proceeding in the United States District Court for the District of New Jersey, drawing investor focus towards the company s recent financial underperformance.As shareholders consider ...
October 31, 2024
FDA Accepts Biologics License Application for HLX14, a Biosimilar to PROLIA/XGEVA, Marks a Significant Move in Osteoporosis Treatment XANGAI, China, and JERSEY CITY, N.J. In a landmark development for the biosimilar landscape, the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for HLX14, a proposed biosimilar to PROLIA/XGEVA (denosumab). This crucial step marks a significant leap forward not only for Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) but also for patients requiring effective treatments for osteoporosis and other conditions related to bone health. Understanding HLX14 and DenosumabDenosumab, marketed under the names PROLIA and XGE...
May 25, 2024
The Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) have recently announced that the European Medicines Agency (EMA) has validated their marketing authorization applications (MAA) for HLX14. This groundbreaking experimental biosimilar drug is designed to replicate the therapeutic effects of Prolia and Xgeva, both of which contain denosumab. Denosumab has gained regulatory approval in several countries under different trade names for treating various indications. This article aims to provide a comprehensive analysis of the significance of EMA s validation, the potential impact of biosimilar HLX14, and its implications for the pharmaceutical industry.The Criticality of EMA s Validation:EMA s v...
May 7, 2024
Organon, a global healthcare company specializing in women s health, has made a significant announcement today regarding a proposed $1.0 billion senior notes offering. This move reflects Organon s focused efforts to strengthen its position in the market, support ongoing research and development initiatives, and expand its presence in the field of women s healthcare. By exploring this offering, Organon aims to reinforce its commitment to enhancing the lives of women worldwide.Organon, a prominent name in the healthcare industry, has recently announced its plan to offer senior secured notes and senior unsecured notes, amounting to $500 million each, due in 2034. This strategic decision demonstrates Organon s d...
Organon and Eli Lilly Forge Strategic Partnership for Migraine Medications in Europe Amidst Competitive Revenue Declines The pharmaceutical giants Organon (NYSE: OGN) and Eli Lilly and Company (Lilly) have announced a strategic agreement, placing Organon as the exclusive distributor and promoter of two premium migraine medicines, Emgality (Galcanezumab) and RAYVOW (Lasmiditan) across Europe. This announcement comes as Organon continues to focus on women s health on the global health platform. Located in Jersey City, N.J., this healthcare leader forges ahead with this novel partnership against a challenging commercial backdrop evidenced by a comparative annualized decrease in third-quarter revenues f...
In the third quarter of 2023, amid a complex market backdrop, global life science company Organon (NYSE: OGN) reported a year-on-year revenue decrease of -1.17%. Despite this decline, Organon appears to be holding up well compared to its competitors, which recorded the same decrease in earnings during the same quarter. A closer look at the financials reveals a significant contraction of net income. Organon and Co s net income in the third quarter of 2023 shrank year on year by -74.45%, a sharp decline mirrored by most of its competitors. With a net margin of 3.82%, the company reported lower profitability than its peers. The NYSE-listed firm Organon is not new to the challenges of the pharmace...
Tempest Therapeutics Inc is a biotechnology company focused on developing small molecule therapeutics to treat cancer and other diseases. Their business model revolves around identifying novel targets within the immune system and designing drugs that modulate these targets to enhance the body's immune response against cancer cells. Through strategic collaborations and partnerships, they aim to accelerate the development and commercialization of their product candidates.
Fortress Biotech Inc operates as a biopharmaceutical company that acquires, develops, and commercializes novel pharmaceutical and biotechnology products. Their business model focuses on partnering with academic institutions and biotech companies to advance preclinical and clinical-stage therapies for various diseases. Additionally, they aim to leverage their expertise and partnerships to improve the development process and bring innovative treatments to patients in need.
Pulmatrix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative inhaled therapies for respiratory diseases. Their business model revolves around creating novel inhaled drug delivery technologies and collaborating with partners to advance their product pipeline, aiming to provide effective treatments for patients with respiratory conditions.
Sources:
Organon and Co’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Organon and Co versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
